Table 3.
Selected Trials of Elotuzumab in Multiple Myeloma (MM)
| Trial ID (References) | Treatment | Phase | Enrollment (N) | Trial Title |
|---|---|---|---|---|
| NCT0271883384 | Elo + Pom + Bort + Dex | II | 52 | A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in RRMM |
| NCT0215936585 | Elo + Len + Dex | II | 84 | A phase II single arm study of safety of elotuzumab administered over approximately 60 minutes in combination with lenalidomide and dexamethasone for newly diagnosed or RRMM patients |
| NCT0147804886 | (Bort + Dex) ± Elo | II | 185 | A Phase II, randomized study of bortezomib/dexamethasone with or without elotuzumab in subjects with RRMM |
| NCT0144197387,88 | Elo | II | 41 | A phase II biomarker study of elotuzumab monotherapy to assess the association between NK cell status and efficacy in high risk smoldering myeloma |
| NCT0265413279 | (Pom + Dex) ± Elo | II | 157 | An open label, randomized phase II trial of pomalidomide and dexamethasone with or without elotuzumab in RRMM (ELOQUENT-3) |
| NCT0249592289 | (Len + Bort + Dex) ± Elo | III | 564 | A randomized phase III trial on the effect of elotuzumab in VRd induction /consolidation and lenalidomide maintenance in patients with newly diagnosed MM |
| NCT0166871981,90 | (Len + Bort + Dex) ± Elo | I/II | 122 | A randomized phase I/II study of optimal induction therapy of bortezomib, dexamethasone, and lenalidomide with or without elotuzumab for newly diagnosed high risk MM |
| NCT0123979777,78,91–94 | (Len + Dex) ± Elo | III | 761 | Phase III, randomized, open label trial of lenalidomide and dexamethasone with or without elotuzumab in RRMM (ELOQUENT-2) |
| NCT0074256095 | Elo + Len + Dex | II | 101 | A phase Ib/II, multicenter, open-label, dose-escalation study of elotuzumab in combination with lenalidomide and dexamethasone in subjects with RRMM |
| NCT0272658196 | (Pom + Niv + Elo + Dex) vs (Pom + Dex ± Niv) | III | 348 | An open-label, randomized phase III trial of combinations of nivolumab, pomalidomide and dexamethasone in RRMM |
Abbreviations: Bort, bortezomib; Dex, dexamethasone; Elo, elotuzumab; Len, lenalidomide; Niv, nivolumab; Pom, pomalidomide.